Abstract
As renal artery stenting becomes more commonly performed, the prevalence of renal artery in-stent restenosis will increase. Intracoronary brachytherapy is the only adjuvant therapy that has been shown to reduce the incidence of recurrent restenosis. This review addresses the mechanisms that make brachytherapy an effective tool for restenosis and its application to renal arteries. To date, the literature on renal artery brachytherapy for restenosis consists of several singular case reports and two case series. The first series of 13 patients had a 20% restenosis rate 1 year after brachytherapy, when Doppler ultrasound was used for follow-up monitoring. A report of a series of 5 patients, published this year, used surrogate markers for assessing efficacy as endpoints and found a similar restenosis rate. These series and case reports demonstrate that renal brachytherapy is feasible and safe. Comments on efficacy must await a randomized trial or accumulation of more anecdotal data.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
